1297 COMPARISON OF PROPHYLACTIC NAFTOPIDIL, TAMSULOSIN AND SILODOSIN FOR 125I BRACHYTHERAPY-INDUCED LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH PROSTATE CANCER: RANDOMIZED CONTROLLED TRIAL

Abstract

You have accessJournal of UrologyProstate Cancer: Localized1 Apr 20111297 COMPARISON OF PROPHYLACTIC NAFTOPIDIL, TAMSULOSIN AND SILODOSIN FOR 125I BRACHYTHERAPY-INDUCED LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH PROSTATE CANCER: RANDOMIZED CONTROLLED TRIAL Hideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, Ken-ichi Tabata, Tetsuo Fujita, Masaki Kimura, Kazushige Hayakawa, and Shiro Baba Hideyasu TsumuraHideyasu Tsumura Sagamihara, Japan More articles by this author , Takefumi SatohTakefumi Satoh Sagamihara, Japan More articles by this author , Hiromichi IshiyamaHiromichi Ishiyama Sagamihara, Japan More articles by this author , Ken-ichi TabataKen-ichi Tabata Sagamihara, Japan More articles by this author , Tetsuo FujitaTetsuo Fujita Sagamihara, Japan More articles by this author , Masaki KimuraMasaki Kimura Sagamihara, Japan More articles by this author , Kazushige HayakawaKazushige Hayakawa Sagamihara, Japan More articles by this author , and Shiro BabaShiro Baba Sagamihara, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.997AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To compare the efficacy of three alpha1A/alpha1D-adrenoceptor (AR) antagonists, naftopidil, tamsulosin and silodosin, that have differing affinity for the alpha1-AR subtypes in treating urinary morbidities in Japanese men with 125I prostate implantation (PI) for prostate cancer. METHODS This single-institution prospective randomized controlled trial compared naftopidil, tamsulosin and silodosin in patients undergoing PI. Patients were received either naftopidil, tamsulosin or silodosin. Treatment began one day after PI and continued for one year. The primary efficacy variables were the changes in the total International Prostate Symptom Score (IPSS) and post-void residual urine (PVR). The secondary efficacy variables were changes in the IPSS storage score, IPSS voiding score and IPSS quality-of-life (QoL) score from baseline to set points during the study (1, 3, 6 and 12 months). RESULTS 212 patients were evaluated in this study: 71, 70 and 71 patients in the naftopidil, tamsulosin and silodosin groups, respectively. With respect to primary efficacy variables, the mean change in the total IPSS at 1 month after PI in the naftopidil, tamsulosin and silodosin groups was +10.3, +8.9 and +7.5, respectively. There were significantly greater decreases with silodosin than naftopidil at 1 month in the total IPSS (Fig. 1A). The mean change in PVR at 6 months was +14.6, +23.7 and +5.7 mL in the naftopidil, tamsulosin and silodosin groups, respectively; silodosin showed a significant improvement in PVR at 6 months vs tamsulosin (Fig. 1B). With respect to secondary efficacy variables, the mean change in the IPSS voiding score at 1 month in the naftopidil, tamsulosin and silodosin groups were +6.5, +5.6 and +4.5, respectively; silodosin showed a significant improvement in the IPSS voiding score at 1 month vs naftopidil (Fig. 1C). The mean change in the IPSS QoL score at 3 months in the naftopidil, tamsulosin and silodosin groups was +1.3, +1.4 and +0.9, respectively. There were significantly greater decreases with silodosin than tamsulosin in the IPSS QoL score at 3 months (Fig. 1D). CONCLUSIONS Silodosin has a greater impact on improving PI-induced urinary morbidities than the other two agents. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e519 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hideyasu Tsumura Sagamihara, Japan More articles by this author Takefumi Satoh Sagamihara, Japan More articles by this author Hiromichi Ishiyama Sagamihara, Japan More articles by this author Ken-ichi Tabata Sagamihara, Japan More articles by this author Tetsuo Fujita Sagamihara, Japan More articles by this author Masaki Kimura Sagamihara, Japan More articles by this author Kazushige Hayakawa Sagamihara, Japan More articles by this author Shiro Baba Sagamihara, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...